Opis

• Tytuł:
  Efficacy and Safety of Miebo® (Perfluorohexyloctane Ophthalmic Solution) in Treating Dry Eye Disease - a narrative review
• Twórca:
  Nowoświat, Patrycja;
  Kozicz, Michał Andrzej;
  Cuper, Paulina;
  Jastrzębska, Ilona;
  Bilecki, Krzysztof;
  Gugulski, Hubert;
  Bado, Michał;
  Mrowczyk, Patrycja
• Opis:
  Introduction: Dry eye disease (DED) is a prevalent and debilitating ocular condition characterized by discomfort, visual disturbances, and tear film instability. Recent therapeutic developments have introduced perfluorohexyloctane ophthalmic solution (Miebo®) as a potential treatment for DED, particularly in patients with meibomian gland dysfunction (MGD). Aim of the Study: This narrative review aims to evaluate the efficacy and safety of Miebo® in treating DED based on current clinical evidence. Materials and Methods: A comprehensive literature search was conducted in PubMed, Embase, and Cochrane Library databases up to May 2024 resulting in the identification of 9 studies. The review included randomized controlled trials, prospective cohort studies, and systematic reviews that focused on the use of Miebo® for DED. Data on efficacy in improving tear film stability and symptom relief, as well as safety profiles, were extracted and analyzed. Results: The evidence indicates that Miebo® significantly enhances tear film stability and alleviates symptoms of DED, with pronounced benefits observed in patients with MGD. Comparative studies demonstrate that Miebo® is more effective than conventional treatments, such as artificial tears and lipid-based formulations. Safety assessments reveal minimal ocular surface discomfort and no significant systemic adverse events associated with Miebo® use. Conclusion: Miebo® shows substantial efficacy and a favorable safety profile in managing DED, making it a valuable therapeutic option, particularly for patients who do not respond to traditional therapies. However, further research is needed to confirm its long-term effectiveness and safety.
• Dostępność obiektu:
  Dostęp otwarty
• Prawa:
  Prawa autorskie (c) 2024 Patrycja Nowoświat, Michał Andrzej Kozicz, Paulina Cuper, Ilona Jastrzębska, Krzysztof Bilecki, Hubert Gugulski, Michał Bado, Patrycja Mrowczyk;
  https://creativecommons.org/licenses/by-nc-sa/4.0
• Data:
  2024.07.16
• Typ:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Język:
  angielski
• Źródło:
  Quality in Sport; Tom 16 (2024); 52893;
  Quality in Sport; Vol. 16 (2024); 52893;
  2450-3118
• Format:
  application/pdf
• Wydawca:
  University Center for Sports Research, Nicolaus Copernicus University, Torun, Poland
• Relacja: https://apcz.umk.pl/QS/article/view/52893/39105
• Temat i słowa kluczowe:
  Dry eye disease;
  perfluorohexyloctane;
  Miebo®;
  meibomian gland dysfunction;
  efficacy;
  safety
• Identyfikator: https://apcz.umk.pl/QS/article/view/52893
• Dostawca danych:
  Akademicka Platforma Czasopism
• Czy mogę z tego obiektu skorzystać?:
  poproś o pozwolenie
• Rodzaj zawartości:
  teksty